Brainsway AI Stock Analysis
Brainsway (BRSYF) AI Stock Analysis
Brainsway
(Other OTC:BRSYF)
No summary available
Brainsway (BRSYF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.29B
- Dividend Yield
- ―
- Average Volume (3M)
- 259
- Price to Earnings (P/E)
- 41.2
- Beta (1Y)
- 0.52
- Revenue Growth
- 33.07%
- EPS Growth
- 53.24%
- Country
- US
- Employees
- 129
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Brainsway Business Overview & Revenue Model
Company Description
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's...
Brainsway Earnings Call Summary
The call was strongly positive, marked by 34% revenue growth, 44% growth in system shipments, expanding gross and operating margins, higher cash flow, increased reimbursement coverage, strong demand for SWIFT and OCD, and an outlook at the upper end of or potentially modestly above prior guidance. The company also reported preliminary clinical results, pending regulatory work, early-stage home-use commercialization and higher operating expenses, but these issues did not outweigh the reported financial and commercial progress.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, management expects results to be at the upper end of its previously issued guidance range, with the potential to modestly exceed those ranges; operating income is expected to be in the upper end of guidance. For 2027, management said there is no formal guidance, but expects operating expenses to increase between 15% to 20%, to continue and increase the margin, and cited book-to-bill of around 1.3 -- 1.4x. Management also expects international revenue growth of between 50% or even 100%, expects partnerships to open up between 50, sometimes even more locations in the next 3 years, and said the Alzheimer's feasibility study is expected to be completed by end of 2027, with a potential multicenter clinical trial costing between $3 million to $4 million over 2.5 or 3 years.
Brainsway Risk Analysis
Brainsway disclosed 67 risk factors in its most recent earnings report. Brainsway reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksBrainsway Peers Comparison
Overall Rating
IL:SOFW72Outperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | ILS 1.27B | 31.48 | ― | ― | 25.84% | 1717.73% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BRSYF | Brainsway | 10.43 | 2.43 | 30.31% | |
| IL:ILX | ILEX Medical Ltd. | 4790.00 | -1940.10 | -28.83% | |
| IL:ALMD | Allmed Solutions Ltd. | 30.10 | -2.00 | -6.23% | |
| IL:EPIT | EPITOMEE MEDICAL LTD | 263.30 | -463.30 | -63.76% | |
| IL:SOFW | Sofwave Medical Ltd. | 3454.00 | 529.00 | 18.09% | |
| IL:PLSM | Pulsenmore | 464.00 | -2108.49 | -81.96% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
